Liposome technologies towards colorectal cancer therapeutics

Sang, Rui; Stratton, Bradley; Engel, Alexander; Deng, Wei

doi:10.1016/j.actbio.2021.03.055

Cited by 45 publications

(32 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposomal delivery system appears to be one of the most promising nanocarriers for CRC treatment. In the last three years, this delivery system has entered extensive preclinical research for CRC therapy [3,131]. Liposome-based nanoproducts, presently under clinical investigations for CRC treatment, are CPX-1, LE-SN38 and Thermodox.…”

Section: Liposomes As Colorectal Therapeuticsmentioning

confidence: 99%

Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials

Krasteva

Georgieva

2022

Pharmaceutics

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a global health problem responsible for 10% of all cancer incidences and 9.4% of all cancer deaths worldwide. The number of new cases increases per annum, whereas the lack of effective therapies highlights the need for novel therapeutic approaches. Conventional treatment methods, such as surgery, chemotherapy and radiotherapy, are widely applied in oncology practice. Their therapeutic success is little, and therefore, the search for novel technologies is ongoing. Many efforts have focused recently on the development of safe and efficient cancer nanomedicines. Nanoparticles are among them. They are uniquewith their properties on a nanoscale and hold the potential to exploit intrinsic metabolic differences between cancer and healthy cells. This feature allows them to induce high levels of toxicity in cancer cells with little damage to the surrounding healthy tissues. Graphene oxide is a promising 2D material found to play an important role in cancer treatments through several strategies: direct killing and chemosensitization, drug and gene delivery, and phototherapy. Several new treatment approaches based on nanoparticles, particularly graphene oxide, are currently under research in clinical trials, and some have already been approved. Here, we provide an update on the recent advances in nanomaterials-based CRC-targeted therapy, with special attention to graphene oxide nanomaterials. We summarise the epidemiology, carcinogenesis, stages of the CRCs, and current nanomaterials-based therapeutic approaches for its treatment.

show abstract

Section: Liposomes As Colorectal Therapeuticsmentioning

confidence: 99%

Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials

Krasteva

Georgieva

2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…[ 73 ] In addition, the incorporation of a stimuli‐responsive function with respect to the endogenous chemical trigger signals from tumors such as pH and enzymes or the exogenous signals, for instance, temperature, light, X‐ray, and ultrasound has also be an important issue associated with liposomal‐mediated cancer therapy in recent years. [ 74 ] Typically, the addition of active agents either organic or inorganic ones or the tuning of the lipid components have been extensively used to render the stimuli‐responsive function for liposomes. Taking light‐responsive liposomes as an example, a near infrared (NIR) light can be employed as a light signal when a liposomal formulation was incorporated with indocyanine green (ICG) [ 75,76 ] or gold NPs (AuNPs).…”

Section: Organic‐based Nanostructured Carriersmentioning

confidence: 99%

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Yang

Lin

Chen

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

Since the conceptualization of nanomedicine, numerous nanostructure‐mediated drug formulations have progressed into clinical trials for treating cancer. However, recent clinical trial results indicate such kind of drug formulations has a limited improvement on the antitumor efficacy. This is due to the biological barriers associated with those formulations, for example, circulation stability, extravasation efficiency in tumor, tumor penetration ability, and developed multi‐drug resistance. When employing for nanomedicine formulations, pristine organic‐based and inorganic‐based nanostructures have their own limitations. Accordingly, organic/inorganic (O/I) hybrids have been developed to integrate the merits of both, and to minimize their intrinsic drawbacks. In this context, the recent development in O/I hybrids resulting from a self‐assembly strategy will be introduced. Through such a strategy, organic and inorganic building blocks can be self‐assembled via either chemical covalent bonds or physical interactions. Based on the self‐assemble procedure, the hybridization of four organic building blocks including liposomes, micelles, dendrimers, and polymeric nanocapsules with five functional inorganic nanoparticles comprising gold nanostructures, magnetic nanoparticles, carbon‐based materials, quantum dots, and silica nanoparticles will be highlighted. The recent progress of these O/I hybrids in advanced modalities for combating cancer, such as, therapeutic agent delivery, photothermal therapy, photodynamic therapy, and immunotherapy will be systematically reviewed.

show abstract

“…21 Although several types of liposome-based nanocarriers have been approved by Food and Drug Administration (FDA) for clinical uses, liposomes are unstable in physiological media and thus further multifarious processes (with additional materials) are required to improve their stability. 22,23 Mesoporous silica NPs with tailorable interior/ exterior surface properties can be designed to selectively carry hydrophilic and hydrophobic drugs of interest. 24 However, the biodegradation and biodistribution of mesoporous silica NPs are impediments in advancing their clinical applications.…”

mentioning

confidence: 99%

“…Nanocarriers such as liposomes and mesoporous silica nanoparticles (NPs) and other functional NPs have been demonstrated as effective nanosystems for synchronic delivery of multiple drugs and disease treatments. − Because of their intrinsic structures, liposomes are able to encapsulate both hydrophilic and hydrophobic drugs in their core and shell, respectively . Although several types of liposome-based nanocarriers have been approved by Food and Drug Administration (FDA) for clinical uses, liposomes are unstable in physiological media and thus further multifarious processes (with additional materials) are required to improve their stability. , Mesoporous silica NPs with tailorable interior/exterior surface properties can be designed to selectively carry hydrophilic and hydrophobic drugs of interest . However, the biodegradation and biodistribution of mesoporous silica NPs are impediments in advancing their clinical applications .…”

mentioning

confidence: 99%

Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration

et al. 2022

View full text Add to dashboard Cite

The development of therapeutics for effective treatments of retinal diseases is significantly constrained by various biological barriers. We herein report a nanomedicine strategy to develop nanotherapeutics featured with not only high retinal permeability but also sustained bioactive delivery. Specifically, the nanotherapeutics are rationally designed via aminolysis of resveratrol-encapsulated polycaprolactone nanoparticles (R@PCL NPs), followed by the formation of amide linkages with carboxyl-terminated transacting activator of transcription cell penetrating peptide (T) and metformin (M). The R@PCL-T/M NP nanotherapeutics are demonstrated in vitro to possess persistent drug release profiles, good ocular biocompatibility, and potent bioactive activities for targeting prevailing risk factors associated with retinal diseases. In vivo studies indicate that single-dose intravitreal administration of the R@PCL-T/M NPs can effectively improve retinal permeability (∼15-fold increase), prevent loss of endogenous antioxidants, and suppress the growth of abnormal vessels in the retina with macular degeneration for 56 days. This high treatment efficacy can be ascribed to the enhanced retinal permeability of the nanotherapeutics in conjunction with the sustained pharmacological activity of the dual drugs (R and M) in the retinal pigment epithelial region. These findings show a great promise for the development of pharmacological nanoformulations capable of targeting the retina and thereby treating complex posterior segment diseases with improved efficacies.

show abstract

Liposome technologies towards colorectal cancer therapeutics

Cited by 45 publications

References 207 publications

Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials

Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials

Organic/Inorganic Self‐Assembled Hybrid Nano‐Architectures for Cancer Therapy Applications

Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration

Contact Info

Product

Resources

About